Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale DC, Deyà-Martinez À, Dickerson KE, Ezra N, Hasle H, Kang HJ, Kiani-Alikhan S, Kuijpers TW, Kulagin A, Langguth D, Levin C, Neth O, Olbrich P, Peake J, Rodina Y, Rutten CE, Shcherbina A, Tarrant TK, Vossen MG, Wysocki CA, Belschner A, Bridger GJ, Chen K, Dubuc S, Hu Y, Jiang H, Li S, MacLeod R, Stewart M, Taveras AG, Yan T, Donadieu J.
Badolato R, et al. Among authors: langguth d.
Blood. 2024 Apr 21:blood.2023022658. doi: 10.1182/blood.2023022658. Online ahead of print.
Blood. 2024.
PMID: 38643510